drugset / Trial / NCT06973681

A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese Subjects

NCT06973681

Phase 2 Completed 120 enrolled BrightGene Bio-Medical Technology Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

To assess the effect of BGM0504 injection versus placebo on weight loss in overweight or obese subjects after 24 weeks of treatment.

Timeline

Start
2023-10-13
Primary completion
2024-09-13
Completion
2024-09-13

Drugs

EvaluationDrugModalityDoseRoute
Subject BGM0504 Unknown 5 mg Subcutaneous
Subject BGM0504 Unknown 10 mg Subcutaneous
Subject BGM0504 Unknown 15 mg Subcutaneous

Indications